Christophe Deben

2.2k total citations · 1 hit paper
49 papers, 1.5k citations indexed

About

Christophe Deben is a scholar working on Oncology, Molecular Biology and Biomedical Engineering. According to data from OpenAlex, Christophe Deben has authored 49 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 26 papers in Molecular Biology and 11 papers in Biomedical Engineering. Recurrent topics in Christophe Deben's work include Cancer Cells and Metastasis (11 papers), Cancer-related Molecular Pathways (9 papers) and Cancer Genomics and Diagnostics (7 papers). Christophe Deben is often cited by papers focused on Cancer Cells and Metastasis (11 papers), Cancer-related Molecular Pathways (9 papers) and Cancer Genomics and Diagnostics (7 papers). Christophe Deben collaborates with scholars based in Belgium, Netherlands and United States. Christophe Deben's co-authors include Filip Lardon, Evelien Smits, Patrick Pauwels, Marc Peeters, An Wouters, Julie Jacobs, Jinthe Van Loenhout, Jorrit De Waele, Vanessa Deschoolmeester and Annemie Bogaerts and has published in prestigious journals such as International Journal of Cancer, Advanced Science and Journal of Physics D Applied Physics.

In The Last Decade

Christophe Deben

49 papers receiving 1.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The potential and controversy of targeting STAT family members in cancer

2019 273 citations Yannick Verhoeven, Julie Jacobs et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christophe Deben Belgium	20	652	617	301	255	240	49	1.5k
Jianghong Deng China	21	1.2k 1.9×	596 1.0×	337 1.1×	179 0.7×	182 0.8×	54	1.9k
Sang‐Yeob Kim South Korea	24	797 1.2×	440 0.7×	262 0.9×	271 1.1×	240 1.0×	81	1.6k
Donald J. Johann United States	18	805 1.2×	389 0.6×	315 1.0×	126 0.5×	205 0.9×	59	1.4k
Guangyu Yao China	20	638 1.0×	359 0.6×	294 1.0×	226 0.9×	176 0.7×	45	1.4k
Shiwei Guo China	24	571 0.9×	524 0.8×	286 1.0×	188 0.7×	168 0.7×	89	1.5k
Gianfranco De Feo Italy	5	1.0k 1.5×	728 1.2×	225 0.7×	121 0.5×	387 1.6×	9	1.8k
Fernando Doñate United States	22	897 1.4×	508 0.8×	341 1.1×	224 0.9×	145 0.6×	56	1.8k
Beihua Kong China	29	990 1.5×	523 0.8×	525 1.7×	409 1.6×	334 1.4×	99	2.3k
Yiding Chen China	21	975 1.5×	710 1.2×	526 1.7×	145 0.6×	247 1.0×	86	2.0k

Countries citing papers authored by Christophe Deben

Since Specialization

Citations

This map shows the geographic impact of Christophe Deben's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christophe Deben with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christophe Deben more than expected).

Fields of papers citing papers by Christophe Deben

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christophe Deben. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christophe Deben. The network helps show where Christophe Deben may publish in the future.

Co-authorship network of co-authors of Christophe Deben

This figure shows the co-authorship network connecting the top 25 collaborators of Christophe Deben. A scholar is included among the top collaborators of Christophe Deben based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christophe Deben. Christophe Deben is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Privat‐Maldonado, Angela, Jonas R.M. Van Audenaerde, Jorrit De Waele, et al.. (2025). Capturing the Heterogeneity of the PDAC Tumor Microenvironment: Novel Triple Co-Culture Spheroids for Drug Screening and Angiogenic Evaluation. Cells. 14(6). 450–450. 2 indexed citations

Deben, Christophe, Laurie Freire Boullosa, Edgar Cardenas De La Hoz, et al.. (2024). Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition. Journal of Experimental & Clinical Cancer Research. 43(1). 8 indexed citations

Deben, Christophe, Edgar Cardenas De La Hoz, Steve Vanlanduit, et al.. (2024). Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assays. Communications Biology. 7(1). 1612–1612. 3 indexed citations

Graaff, Denise van der, et al.. (2024). Advancements in Research and Treatment Applications of Patient-Derived Tumor Organoids in Colorectal Cancer. Cancers. 16(15). 2671–2671. 1 indexed citations

Zwaenepoel, Karen, Wiebren Tjalma, Christophe Deben, et al.. (2023). Urine biomarkers in cancer detection: A systematic review of preanalytical parameters and applied methods. International Journal of Cancer. 152(10). 2186–2205. 34 indexed citations

Arora, Amit, Kyle W. MacDonald, Jhana O. Hendrickx, et al.. (2023). UAS™—A Urine Preservative for Oncology Applications. Cancers. 15(12). 3119–3119. 4 indexed citations

Hoz, Edgar Cardenas De La, Evelien Smits, Filip Lardon, et al.. (2022). Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis. Journal of Visualized Experiments. 10 indexed citations

Sarno, Federica, Emilie Logie, Christophe Deben, et al.. (2022). Functional Validation of the Putative Oncogenic Activity of PLAU. Biomedicines. 11(1). 102–102. 7 indexed citations

Deben, Christophe, Edgar Cardenas De La Hoz, Paul Van Schil, et al.. (2022). OrBITS: label-free and time-lapse monitoring of patient derived organoids for advanced drug screening. Cellular Oncology. 46(2). 299–314. 41 indexed citations

10.

Domen, Andreas, Delphine Quatannens, Sara Zanivan, et al.. (2021). Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. Cancers. 13(5). 987–987. 42 indexed citations

11.

Deben, Christophe, Laurie Freire Boullosa, Andreas Domen, et al.. (2021). Characterization of acquired nutlin-3 resistant non-small cell lung cancer cells. Cancer Drug Resistance. 4(1). 233–243. 10 indexed citations

12.

Jacobs, Julie, Christophe Deben, Christophe Hermans, et al.. (2020). Mass Spectrometry Imaging Reveals Neutrophil Defensins as Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC Patients. Cancers. 12(4). 863–863. 19 indexed citations

13.

Bossche, Jolien Van den, Andreas Domen, Marc Peeters, et al.. (2019). Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status. Cancers. 11(12). 1893–1893. 9 indexed citations

14.

Bossche, Jolien Van den, Christophe Deben, Ines De Pauw, et al.. (2019). In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53. Molecular Oncology. 13(5). 1196–1213. 15 indexed citations

15.

Lin, Abraham, Wilma Van Boxem, Jinthe Van Loenhout, et al.. (2019). The Influence of Cell Type and Culture Medium on Determining Cancer Selectivity of Cold Atmospheric Plasma Treatment. Cancers. 11(9). 1287–1287. 89 indexed citations

16.

Jacobs, Julie, Vanessa Deschoolmeester, Karen Zwaenepoel, et al.. (2018). Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation. OncoImmunology. 7(7). e1440167–e1440167. 45 indexed citations

17.

Deben, Christophe, Vanessa Deschoolmeester, Jorrit De Waele, et al.. (2018). Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress. Cancers. 10(4). 126–126. 46 indexed citations

18.

Waele, Jorrit De, Elly Marcq, Jonas R.M. Van Audenaerde, et al.. (2017). Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade. OncoImmunology. 7(3). e1407899–e1407899. 36 indexed citations

19.

Steen, Nele Van Der, Christophe Deben, Vanessa Deschoolmeester, et al.. (2016). Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer. World Journal of Clinical Oncology. 7(6). 425–425. 9 indexed citations

20.

Deben, Christophe, Filip Lardon, An Wouters, et al.. (2016). APR-246 (PRIMA-1 MET ) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines. Cancer Letters. 375(2). 313–322. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact